Information  X 
Enter a valid email address

FastForward Inn Ltd (FFWD)

  Print   

Thursday 11 March, 2021

FastForward Inn Ltd

Sale of Investments in Kanabo and Cellular Goods

RNS Number : 9353R
FastForward Innovations Limited
11 March 2021
 

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

11 March 2021

FastForward Innovations Ltd ("FastForward", "the Company" or, "FFWD")

 

Sale of Investments in Kanabo and Cellular Goods

 

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to announce that following the announcements on 16 February and 1 March respectively regarding the Company's investments in Kanabo Group Plc ('Kanabo') and Cellular Goods Plc ('Cellular Goods'), FastForward has now sold its entire holding in both companies providing the Company with gross profits of £194,414.39.

 

Highlights

· Sale of shares in Kanabo resulted in a profit of £139,851.68, an increase of 223% in value since the Company's original investment

· Sale of shares in Cellular Goods resulted in a profit of £54,562.71, an increase of 315% in value since the Company's original investment

· Proceeds will be used to make further investments in accordance with FastForward's investing policy

 

Ed McDermott, CEO of FastForward Innovations, commented: "Whilst we were disappointed to be heavily scaled back due to both placings being oversubscribed, we are delighted to have made such significant returns on our investments in Kanabo and Cellular Goods in a short timeframe. With our already strong balance sheet, the proceeds from these sales, along with the significant funds to be received from the sale of EMMAC as announced yesterday, will put FastForward in a very strong cash position and enable us to invest in other new and exciting businesses that will bring value to shareholders.  We hope to provide further updates on developments in this regard in due course."

 

Further Information

As announced on 16 February 2021, FastForward invested £62,500 as part of a £6 million oversubscribed placing at a price of 6.5 pence undertaken by Kanabo, which commenced trading on the London Stock Exchange on the same day (LSE: KNB), following a reverse takeover of Spinnaker Opportunities Plc.

 

FastForward completed the sale of its entire holding of 961,538 shares on 8 March providing the Company with total proceeds of £202,684.15 equating to an average net sale price of £0.211 per share. As such, FastForward has made a profit of £139,851.68, which is a total return of 3.23 times the original investment.

 

As announced on 1 March 2021, FastForward invested approximately £17,215 as part of a heavily oversubscribed £13 million placing at a price of 5 pence undertaken by Cellular Goods, which commenced trading on the London Stock Exchange on 26 February 2021 (LSE: CBX).

 

FastForward completed the sale of its entire holding of 344,277 shares in Cellular Goods on 4 March 2021 providing the Company with total proceeds of £71,862.63 equating to an average net sale price of £0.209 per share. As such, FastForward has made a profit of £54,562.71, which is a total return of 4.15 times the original investment.

 

For further information on the Company please visit www.fstfwd.co   or contact:

Ed McDermott / Lance de Jersey

FastForward Innovations Ltd

Email: [email protected]  

 

James Biddle / Roland Cornish

Beaumont Cornish Limited,

Nomad

 

Tel: +44 (0) 207 628 3396

 

Isabella Pierre / Damon Heath

Shard Capital Partners LLP

 

Tel: (0)207 186 9927

Isabel de Salis / Beth Melluish

St Brides Partners Ltd,

Financial PR

Tel: +44 (0)207 236 1177

 

Notes

FastForward Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISKZGMFNMVGMZG

a d v e r t i s e m e n t